Good evening :)
Place Order
Add to Watchlist

Morepen Laboratories Ltd

MOREPENLAB

Morepen Laboratories Ltd

MOREPENLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,731 cr, stock is ranked 802
High RiskStock is 3.85x as volatile as Nifty
87.210.97% (+0.84)
87.210.97% (+0.84)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,731 cr, stock is ranked 802
High RiskStock is 3.85x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹4,731 cr, stock is ranked 802
High RiskStock is 3.85x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
36.045.58
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Morepen Laboratories Limited is a pharmaceutical company. The Company operates through four segments; they are Active Pharmaceutical Ingredients (API), Domestic Formulations, Diagnostics and Over the Counter (OTC).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.16%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.35% to 0.45%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 27.23%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue486.29599.19610.23772.21862.551,200.131,557.141,423.661,704.401,777.29
Raw Materialssubtract303.71381.14365.10516.38567.65822.131,059.36939.261,060.311,565.94
Power & Fuel Costsubtract7.649.8411.0813.1812.5613.0018.9323.7834.09
Employee Costsubtract58.2969.6976.5395.36109.91135.59164.25154.68181.47
Selling & Administrative Expensessubtract43.7253.4661.0873.3081.7392.40102.60150.78182.36
Operating & Other expensessubtract14.5619.9627.992.8012.706.4365.0169.4973.57
Depreciation/Amortizationsubtract35.2033.9034.3239.9036.9130.2827.6427.9333.4725.66
Interest & Other Itemssubtract10.507.564.362.111.981.79-7.371.983.715.30
Taxes & Other Itemssubtract-0.130.000.180.335.531.4225.0217.0839.2549.12
EPS0.280.530.660.640.752.162.190.781.882.57
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 4PDF
FY 2022

Annual report

PDF

Investor Presentation

May 5PDF
Feb 8PDF
Nov 11PDF
Jul 27PDF
FY 2023

Annual report

PDF

Investor Presentation

May 16PDF
Feb 13PDF
Nov 10PDF
Jul 29PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 7PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Morepen Laboratories Ltd49.205.58
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare MOREPENLAB with any stock or ETF
Compare MOREPENLAB with any stock or ETF
MOREPENLAB
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 2.57%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.82%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding35.65%0.00%1.70%2.08%60.57%

Mar 2024

Jun 2024

Aug 2024

Sep 2024

Shareholding History

SepDec '23MarJunAugSep0.05%0.00%0.00%0.00%0.00%0.00%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Morepen Laboratories Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0008%0.21%0.21%55/102 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

MOREPENLAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Earnings
Morepen Laboratories consolidated net profit rises 63.92% in the September 2024 quarter

Net profit of Morepen Laboratories rose 63.92% to Rs 34.85 crore in the quarter ended September 2024 as against Rs 21.26 crore during the previous quarter ended September 2023. Sales rose 3.78% to Rs 437.73 crore in the quarter ended September 2024 as against Rs 421.77 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales437.73421.77 4 OPM %10.077.96 - PBDT47.8836.37 32 PBT46.0228.68 60 NP34.8521.26 64 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Morepen Laboratories to discuss results

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Morepen Laboratories schedules AGM

Morepen Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 28 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Morepen Laboratories appoints director

Morepen Laboratories has appointed Sharad Jain (DIN: 06423452) as an Independent Director, for a term of 5 consecutive years, effective from 27 August 2024. Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Morepen Labs soars after stellar Q1 performance

Net revenue increased by 14% year-over-year (YoY) to Rs 458.64 crore during the period under review. The company holds a strong position in the Blood Glucometers and Blood Pressure (BP) Monitors markets. In Q1 FY25, the medical devices business recorded revenue of Rs 138 crore, marking a 20% growth year-on-year. Pharma segment Q1 FY25 revenue at Rs 320 crore registered a growth of 11% year-on-year, and it represents 70% of consolidated Q1 FY25 quarterly revenues. EBIDTA improved by 93% to Rs 55.05 crore in Q1 FY25 from Rs 28.51 crore in Q1 FY24. Profit before tax in Q1 FY25 stood at Rs 48.17 crore, up by 135% from Rs 20.51 crore in Q1 FY24. Morepen Laboratories said that the company's Blood Glucometer meter capacity would be doubled to 5.0 million meter pa from the current 2.5 million meter, while strip manufacturing capacity will increase from 500 million strips to 700 million strips per annum within the next 18 months. The company has successfully completed the subscription of a QIP for Rs. 200 crores on 5 August 2024. The issue was oversubscribed by 1.68 times, demonstrating strong confidence from institutional investors. Marquee global investors like Bank of America Securities Europe (BOFA), Samsung India, Citigroup, Societe Generale, Nomura, BNP Paribas, Morgan Stanley and Eminence are some of the select names that have partnered with Morepen, paving the way for a promising future. Sushil Suri, chairman and managing director of Morepen Laboratories, commented on the QIP, stating, 'This strategic fundraise marks a pivotal point in the company's growth journey. With the influx of this new capital, we will accelerate our capacity expansion plans and broaden our market reach.' Morepen Laboratories is an established player in domestic and international Active Pharmaceutical Ingredients ('API') markets. It is also planning to enter the anti-cancer segment by considering development of various potential candidates from list of top 100 synthetic molecules. The company also engaged in home diagnostics products, formulations and grooming products under the brand name GUBB. Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Morepen Laboratories consolidated net profit rises 147.23% in the June 2024 quarter

Net profit of Morepen Laboratories rose 147.23% to Rs 36.17 crore in the quarter ended June 2024 as against Rs 14.63 crore during the previous quarter ended June 2023. Sales rose 13.51% to Rs 455.22 crore in the quarter ended June 2024 as against Rs 401.04 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales455.22401.04 14 OPM %11.346.51 - PBDT53.8928.23 91 PBT48.1720.51 135 NP36.1714.63 147 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Morepen Laboratories to announce Quarterly Result

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Morepen Laboratories successfully concludes QIP issue of Rs 200 cr

Morepen Laboratories announced the successful subscription of a Qualified Institutional Placement (QIP) for Rs. 200 crore. The issue was subscribed 1.68 times with bids of Rs. 335 crore against the Rs. 200 crore offering, demonstrating strong confidence reposed by institutional investors. Marquee global investors like Bank of America Securities Europe (BOFA), Samsung India, Citigroup, Societe Generale, Nomura, BNP Paribas, Morgan Stanley and Eminence are some of the select names that have partnered with Morepen, paving the way for a promising future. Motilal Oswal Investment Advisors was the book running lead manager (BRLM) for the issue. Powered by Capital Market - Live

4 months agoCapital Market - Live

Morepen Laboratories Launches Rs 250-Crore QIP

4 months agoBloomberg Quint

Muthoot Finance, Morepen Laboratories, and Force Motors: What the Charts Say

1 year agoThe Hindu Businessline